Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world adjuvant apatinib after surgery for high-risk hepatocellular carcinoma recurrence
ChiCTR1800018175Phase 4Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Sep 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Chinese PLA General Hospital. Primary endpoints: Recurrence-free survival and Time to recurrence. Started Sep 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1800018175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018175.